Prometheus Biosciences - RXDX Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RXDX shares.
View RXDX analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1 year price objectives for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $55.00 to $181.00. On average, they predict the company's stock price to reach $117.10 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts.

Prometheus Biosciences' stock was trading at $110.00 at the start of the year. Since then, RXDX stock has decreased by 0.3% and is now trading at $109.67.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our RXDX earnings forecast.

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. The biopharmaceutical company had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.77 million. Prometheus Biosciences had a negative net margin of 1,847.71% and a negative trailing twelve-month return on equity of 61.37%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

(RXDX) raised $126 million in an initial public offering on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Waypoint Capital Advisors LLC (0.41%), AR Asset Management Inc. (0.12%), New York State Common Retirement Fund (0.09%), Comerica Bank (0.08%), Moody Aldrich Partners LLC (0.03%) and Legato Capital Management LLC (0.02%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RXDX stock can currently be purchased for approximately $109.67.

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $4.60 billion and generates $3.13 million in revenue each year. The biopharmaceutical company earns $-90,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.